Improved antibody breadth with an extended primary dose interval of COVID-19 vaccine is overcome by boosters
An extended primary dose interval resulted in short-term benefits to humoral immunity but these were transient in the context of subsequent exposures. However, in addition to the public health benefits of wider population access to vaccines, the short-term immunological benefits of extending the dose interval may have been sustained in the absence of boosters. These findings underscore the importance of evaluating dosing intervals during the development of future vaccine candidates.
Authors
- Paul J. McLaren (ORCID: https://orcid.org/0000-0001-6019-7018)
- Karla Cachero (ORCID: https://orcid.org/0000-0002-9039-3164)
- Angela Harris (ORCID: https://orcid.org/0000-0002-2184-0274)
- Ruey‐Chyi Su (ORCID: https://orcid.org/0000-0001-9477-1073)
- Christine Mesa (ORCID: https://orcid.org/0000-0001-8465-5474)
- Myo Minn Oo (ORCID: https://orcid.org/0000-0003-4089-016X)
- Lyle R. McKinnon (ORCID: https://orcid.org/0000-0002-7157-0700)
- Hezhao Ji (ORCID: https://orcid.org/0000-0002-5451-6294)
- T. Blake Ball
- Robert Lorenz Chua (ORCID: https://orcid.org/0000-0001-5945-9957)
- Jonathan Walker
- Kathy Manguiat
- Catherine M. Card (ORCID: https://orcid.org/0000-0002-2561-9649)
- Heidi Wood (ORCID: https://orcid.org/0000-0003-4596-7349)
- Bernard Abrenica
- Rissa Fabia
- Farah Alsattari
- John Kim (ORCID: https://orcid.org/0000-0003-4252-5916)
- J. Ahmed
- Carmen Lopez
- Sandra Kiazyk
- Naima Jahan
- Alyssia Robinson
- Derek Stein
- Winnie W.W. Cheung
- M. Reimer
- Samantha J. Krosta
Institutions
- Public Health Agency of Canada (CA)
- Centre for the AIDS Programme of Research in South Africa (ZA)
- University of Manitoba (CA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-27
- DOI
- https://doi.org/10.3389/fimmu.2025.1529134
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00